Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocol.

Alexander M PopovGuenter HenzeGrigory TsaurOleg BudanovJulia RoumiantsevaMikhail BelevtsevTatiana VerzhbitskayaLiudmila MovchanSvetlana LagoykoLiudmila ZharikovaYulia OlshanskayaTatiana RigerAlena ValochnikNatalia MiakovaDmitry LitvinovOlga KhlebnikovaOlga StrenevaElena StolyarovaNatalia PonomarevaGalina NovichkovaOlga AleinikovaLarisa FechinaAlexander Karachunskiy

Published in: Cancer medicine (2024)

Our data show that combining clinical risk factors with MFC-MRD measurement is the most useful tool for risk group stratification of children with BCP-ALL in the reduced-intensity protocols. However, this algorithm can be supplemented with cytogenetic data for part of the ImR group.

Keyphrases

acute lymphoblastic leukemia
risk factors
young adults
electronic health record
big data
randomized controlled trial
machine learning
deep learning
high intensity
acute myeloid leukemia
data analysis
neural network
breast cancer risk